KLK3 and prostate carcinoma: Although initial management of prostate cancer is difficult, there is even more uncertainty when patients have biochemical recurrence (BCR) prostate cancer (BCRPCa), which is described as a rise in prostate-specific antigen (PSA) levels in patients with prostate cancer who have undergone surgery or radiation (1).